Elevance Health reported stronger-than-expected Q1 results and raised its full-year adjusted EPS guidance, boosting investor confidence. The stock has risen 12.6% since the earnings report. Analysts remain optimistic about margins and valuation, though the stock has lagged the broader market. An insider stock sale by the Chief Accounting Officer occurred but was a routine exercise of vested options.